Research programme: gastrointestinal disorder therapies - Albireo AB

Drug Profile

Research programme: gastrointestinal disorder therapies - Albireo AB

Latest Information Update: 18 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Albireo AB
  • Class
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyspepsia; Gastrointestinal disorders; Inflammatory bowel diseases

Most Recent Events

  • 01 Dec 2014 Discontinued - Preclinical for Inflammatory bowel disease, Gastrointestinal disorders and Dyspepsia in Europe (unspecified route)
  • 08 Oct 2008 Preclinical trials in Dyspepsia in Europe (unspecified route)
  • 08 Oct 2008 Preclinical trials in Gastrointestinal disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top